Pfizer (PFE) Non-Current Debt (2009 - 2026)
Pfizer (PFE) posted quarterly Non-Current Debt of $60.6 billion for Q1 2026, up 5.08% year-over-year from $57.6 billion in Q1 2025, and down 1.75% quarter-over-quarter from $61.6 billion in Q4 2025.
Pfizer (PFE) Non-Current Debt (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Non-Current Debt for 18 consecutive years, with $60.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 5.08% year-over-year to $60.6 billion; the TTM figure through Mar 2026 stood at $60.6 billion (up 5.08% YoY), while the FY2025 annual figure was $61.6 billion, up 7.38% from the prior year.
- Non-Current Debt slipped to $60.6 billion in Q1 2026 per PFE's latest filing, from $61.6 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $62.0 billion in Q4 2023 and bottomed at $31.7 billion in Q2 2023.
- Historically, Non-Current Debt has averaged $52.5 billion across 5 years, with a median of $57.5 billion in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt dropped 11.08% — and 2024, when it soared 93.37%.
- Pfizer's Non-Current Debt stood at $33.0 billion in 2022, then jumped by 87.88% to $62.0 billion in 2023, then slipped by 7.41% to $57.4 billion in 2024, then climbed by 7.38% to $61.6 billion in 2025, then retreated by 1.75% to $60.6 billion in 2026.
- Business Quant data shows PFE's Non-Current Debt at $60.6 billion in Q1 2026, $61.6 billion in Q4 2025, and $57.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 60.50 Bn |
| Mar 29, 2026 | 60.57 Bn |
| Dec 31, 2025 | 61.64 Bn |
| Sep 28, 2025 | 57.41 Bn |
| Jun 29, 2025 | 57.50 Bn |
| Mar 30, 2025 | 57.64 Bn |
| Dec 31, 2024 | 57.41 Bn |
| Sep 29, 2024 | 58.00 Bn |
| Jun 30, 2024 | 57.51 Bn |
| Mar 31, 2024 | 61.31 Bn |
| Dec 31, 2023 | 62.00 Bn |
| Jul 2, 2023 | 61.36 Bn |
| Apr 2, 2023 | 31.70 Bn |
| Dec 31, 2022 | 33.00 Bn |
| Jul 3, 2022 | 34.29 Bn |
| Apr 3, 2022 | 35.66 Bn |
| Dec 31, 2021 | 36.00 Bn |
| Oct 3, 2021 | 36.25 Bn |
| Jul 4, 2021 | 35.35 Bn |
| Apr 4, 2021 | 35.35 Bn |